Description

Lamivudine Tablets

Lamivudine Tablets USP / BP / IP (100 mg / 150 mg / 300 mg)

Essential Nucleoside Reverse Transcriptase Inhibitor (NRTI) Antiviral

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO services provider, and wholesale exporter of advanced antiretrovirals (ARVs), hepatology antivirals, and chronic public health therapeutics. We manufacture an internationally validated, high-capacity range of Lamivudine Tablets within our state-of-the-art, WHO–GMP certified, high-containment solid dosage manufacturing complexes.

Serving as a foundational therapeutic anchor for global viral suppression campaigns, this essential product represents a massive-volume strategic export for national HIV/AIDS control programs, state health ministry tenders, international humanitarian relief pipelines, and digital B2B pharmaceutical marketplaces across Sub-Saharan Africa, the CIS region, LATAM, and South-East Asia.

Product Overview

This formulation operates as a “Viral Genetic Chain Terminator.” It ensures the complete arrest of viral replication and drops systemic viral load by physically mimicking natural genetic building blocks, tricking the virus into incorporating a flawed link that permanently breaks its DNA synthesis pipeline.

• Mechanism 1 (Intracellular Phosphorylation Activation): Lamivudine is a synthetic nucleoside analogue. Upon crossing the target cell membrane, it is physically metabolized by host cellular kinases into its active antiviral metabolite: Lamivudine Triphosphate.

• Mechanism 2 (Competitive Enzyme Target Inhibition): This active chemical structure acts as an absolute structural competitor against the natural substrate, deoxycytidine triphosphate. It binds with high affinity to HIV-1 Reverse Transcriptase or Hepatitis B Virus (HBV) DNA Polymerase, blocking normal viral transcription.

• Mechanism 3 (DNA Chain Termination Execution): The viral enzyme mistakenly incorporates Lamivudine Triphosphate into the growing viral DNA chain. Because the molecule lacks the critical $3\text{‘}$-hydroxyl group required to form a secondary phosphodiester bond, the elongation of the viral DNA chain is physically terminated. This permanently aborts viral replication, preserving host helper T-cell counts and halting progressive hepatic fibrosis.

Product Composition & Available Portfolio strengths

We manufacture Lamivudine across the precise compendial strengths mandated to manage either targeted chronic hepatic monotherapy or high-potency systemic combination antiretroviral protocols.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on infectious diseases / Antivirals / Antiretrovirals)

• CAS Number: 134678-17-4 (Lamivudine)

• Dosage Form: Oral Solid Film-Coated Tablet (Cores are precisely film-coated to provide a robust environmental moisture barrier and ensure easy esophageal passage)

• Packaging Configurations:

  • Institutional Tender Bottles: 30 / 60 Tablets per High-Density Polyethylene (HDPE) Bottle fitted with continuous induction-sealed aluminum foils, tamper-evident outer neck bands, and child-resistant closures featuring integrated internal silica gel desiccants. This is the global standard format for chronic programmatic distribution.

  • Blister Formats: 10 / 14 / 28 Tablets per Blister Strip packed in high-barrier Alu-Alu (Cold-Form Foil) or thick opaque PVC/PVDC matrix strips. Our tropicalized packaging completely prevents environmental moisture vapor transmission, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

High-Containment Antiviral Manufacturing & Quality Assurance

               [ MICRONIZED EXTENDED-PURITY LAMIVUDINE API ]
                                     │
                                     ▼
               [ CLOSED-LOOP ISOLATED GRANULATION SUITE ]
                                     │ (Differential pressure blocks prevent cross-carryover)
                                     ▼
                [ HIGH-SPEED AUTOMATED ROTARY PRESS ]
                                     │ (Online optical and mass verification check)
                                     ▼
                [ SECURE SERIALIZED BOTTLE PACKAGING ]
                                     │ (Integrated anti-counterfeiting tracking codes)
                                     ▼
               [ FLAWLESS ZONE IVb LONG-TERM STABILITY SYNC ]

• Closed-Loop Cross-Contamination Isolation: Because antiretroviral substances must be strictly processed without cross-contamination risks, our manufacturing blocks utilize Dedicated, Isolated Anti-Viral Compression Suites running under strict differential negative pressure. This ensures zero chemical carryover into non-viral manufacturing streams, fully satisfying stringent international B2B regulatory audits.

• High-Velocity Mass Content Uniformity: To easily meet heavy multi-million unit public health tender deadlines, we operate automated, high-output rotary tableting lines equipped with Forced-Feeder Die Matrices and Electronic Online Weight Variation Regulators, physically ensuring absolute microgram-level active drug uniformity across continuous production runs.

• Anti-Counterfeiting Serialization Integrity: For institutional public health shipments, our packaging lines integrate High-Definition Matrix Barcode Serializations, physically embedding unique tracking codes onto each bottle to eliminate counterfeit substitution risks inside destination logistics channels.

Primary Indications

• Immunology & Virology: Part of comprehensive combination Antiretroviral Therapy (ART) for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection in adults and pediatric patients.

• Hepatology: Long-term monotherapy management of Chronic Hepatitis B Virus (HBV) infection in patients presenting with documented evidence of active viral replication and progressive histologically verified hepatic inflammation.

Usage Instructions

• The Uninterrupted Compliance Matrix: Take the tablet orally at exactly the same time each day with a full glass of water. It can be administered consistently either with or without food. Compliance must be absolute; missing doses can chemically lower local drug pressure, physically inducing rapid viral mutation and treatment-failing drug resistance.

• The Dual-Indication Screening Mandate: Advise clinical and pharmacy networks that prior to initializing the low-dose 100 mg Hepatitis B regimen, patients MUST be screened for underlying HIV infection. Utilizing an under-dosed 100 mg tablet in a patient presenting with undiagnosed HIV will chemically force the HIV strain to develop irreversible resistance to Lamivudine, permanently destroying future structural ART therapy lines.

• Renal Clearance Dose Titration: Lamivudine is cleared completely unchanged via renal filtration mechanisms. For patients presenting with documented renal impairment (Creatinine Clearance dropping below 50 mL/min), strict medical dose reductions are clinically mandatory.

Safety Warning: POTENT CHRONIC REVERSE TRANSCRIPTASE INHIBITOR ANTIVIRAL. For Infectious Disease and Hepatology Specialist Supervision Only. The Post-Treatment HBV Exacerbation Warning: If Lamivudine is abruptly discontinued in patients co-infected with Chronic Hepatitis B, a severe, life-threatening Acute Post-Treatment Exacerbation of Hepatitis B can physically manifest, marked by rapid hepatic failure and severe transaminase spikes. Monitor hepatic parameters ($ALT$/$AST$) continuously for several months following therapy cessation. Lactic Acidosis Alert: Nucleoside analogues carry a rare chemical risk of inducing mitochondrial toxicity, physically resulting in Lactic Acidosis and Severe Hepatomegaly with Steatosis. Discontinue therapy immediately if clinical markers point to metabolic acidosis or rapid liver swelling. Contraindications: Absolute contraindications in individuals presenting with documented severe hypersensitivity to lamivudine matrices.

Global CDMO Services & Antiviral Tender Logistics

Healthy Life Pharma Private Limited and Healthy Inc provide comprehensive, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export supply for the entire Lamivudine dosage spectrum. Operating under strict anti-viral containment protocols, we handle all mandatory cross-border documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Zone IVb Stability Testing Data Packs, and Complete CTD Format Dossier sets) for seamless customs entry and rapid national registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Regulatory Helpline: +91 7710003340

• Antiviral Registry Email: info@healthyinc.co.in